R&D; Blueprint and COVID-19
The current COVID-19 pandemic is unprecedented, but the global response draws on the lessons learned from other disease outbreaks over the past several decades.
As part of WHO’s response, the R&D Blueprint was activated to accelerate diagnostics, vaccines and therapeutics for this novel coronavirus. The Blueprint aims to improve coordination between scientists and global health professionals, accelerate the research and development process, and develop new norms and standards to learn from and improve upon the global response.
On 30 January 2020, following the recommendations of the Emergency Committee, the WHO Director-General declared that the outbreak constitutes a Public Health Emergency of International Concern (PHEIC).
World scientists on COVID-19 then met at the World Health Organization’s Geneva headquarters on 11–12 February 2020 to assess the current level of knowledge about the new virus, agree on critical research questions that need to be answered urgently, and to find ways to work together to accelerate and fund priority research to curtail this outbreak and prepare for those in the future.
The discussion led to an agreement on two main goals. The first was to accelerate innovative research to help contain the spread of the epidemic and facilitate care for those affected. The second was to support research priorities that contribute to global research platforms in hopes of learning from the current pandemic response to better prepare for the next unforeseen epidemic.
Building on the response to recent outbreaks of Ebola virus disease, SARS-CoV and MERS-CoV, the R&D Blueprint has facilitated a coordinated and accelerated response to COVID-19, including an unprecedented program to develop a vaccine, research into potential pharmaceutical treatments and strengthened channels for information sharing between countries.Highlights
29 September 2020
COVID-19 Target product profiles for priority diagnostics to support response to the COVID-19 pandemic...
WHO is publishing here the final version of Target Product Profiles (TPP) for priority COVID-19 diagnostics. These TPPs describe the desirable and...
15 June 2020
Feasibility, potential value and limitations of establishing a closely monitored challenge model of experimental...
This is a draft. The content of this document is not final, and the text may be subject to revisions before publication. The document may not be reviewed,...
12 March 2020
A Coordinated Global Research Roadmap
On 11-12 February 2020, WHO, in collaboration with the Global Research Collaboration for Infectious Disease Preparedness and Response (GLOPID-R) –...
12 February 2020
COVID-19 Public Health Emergency of International Concern (PHEIC) Global research and innovation forum
Over the first 6 weeks of the new decade, the novel coronavirus, known as COVID-19, has spread from the People’s Republic of China to 20 other countries.On...
Vaccines
Expert groups
Achievements
Reports
17 April 2020
WHO Working Group – Vaccine Prioritization for COVID-19 Vaccines
17 April 2020
WHO Working Group – Target Product Profiles for COVID-19 Vaccines
17 April 2020
WHO Working Group – Core Protocol for vaccines against COVID-19
17 April 2020
WHO Working Group – Vaccine R&D for COVID-19 Vaccines
17 April 2020
WHO Working Group – Animal Models
20 April 2020
WHO Working Group – Viruses, Reagents and Immune assays
Studies per country, showing study design, type of vaccine, study phase and type of patients.
19 October 2020
Draft landscape of COVID-19 candidate vaccines
13 August 2020
Global animal laboratories capacities to support vaccine and therapeutic evaluation
17 May 2020
Criteria for COVID-19 vaccine prioritization
9 April 2020
WHO Target Product Profiles for COVID-19 Vaccines
5 February 2020
Overview of the types/classes of candidate vaccines against MERS-CoV
5 February 2020
Overview of the types/classes of candidate vaccines against SARS-CoV
30 January 2020
WHO R&D Blueprint novel Coronavirus (nCov) Vaccine prioritization for clinical trials
27 January 2020
WHO R&D Blueprint: novel Coronavirus: prospects for evaluating cross-reactivity of nCoV with SARS-CoV
24 January 2020
WHO Consultation on Cross-Reactivity with other coronaviruses
4 June 2020
COVID-19 Animal Models - Summary of progress made by the WHO COVID-19 modelling (March-04 June 2020)
5 May 2020
Summary of progress made by the WHO assays for vaccines group of experts (18 March – 1 April)
4 April 2020
COVID-19 Animal Models - Summary of progress made by the WHO COVID-19 modelling (15-26 March 2020)
20 March 2020
COVID-19 Animal Models - Summary of progress made by the WHO COVID-19 modelling (27 February - 15 March 2020)
Therapeutics
Expert groups
Achievements
Studies per country, showing study design, disease severity in study participants, and type of treatment being studied, as well as network maps of these studies.
List of treatment comparisons, a summary of the evidence for that comparison, and a detailed description of primary studies, including a risk of bias assessment.
1 October 2020
An international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care
17 June 2020
Targeted Update: Safety and efficacy of hydroxychloroquine or chloroquine for treatment of COVID-19
28 April 2020
COVID 19 candidate treatments
17 January 2020
Outline of designs for experimental vaccines and therapeutics
Reports
29 July 2020
WHO target product profiles for COVID-19 therapeutics
19 June 2020
Informal consultation on the potential inclusion of Sofosbuvir/Daclatasvir in a clinical trial - 19 June 2020
13 May 2020
Informal consultation on the potential inclusion of Immunomodulators in a clinical trial - 13 May 2020
8 May 2020
Informal consultation on the dose of chloroquine and hydroxychloroquine for the SOLIDARITY Clinical Trial - 8 April 2020
7 May 2020
Clinical Trial Design Working Group – consultation on immunomodulators - 7th May 2020
6 May 2020
Informal consultation on the potential inclusion of Immunomodulators in a clinical trial - 6 May 2020
1 May 2020
Informal consultation on the role of therapeutics in COVID-19 prophylaxis and post-exposure prophylaxis - 1 May 2020
16 April 2020
Informal consultation on the role of therapeutics in COVID-19 prophylaxis and post-exposure prophylaxis - 16 April 2020
15 April 2020
Informal consultation on the role of therapeutics in COVID-19 prophylaxis and post-exposure prophylaxis - 15 April 2020
11 April 2020
Informal consultation on the potential role of interleukin-6 blockers in the clinical management of COVID-19 infection - 11th April 2020
10 April 2020
Informal consultation on the role of therapeutics in COVID-19 prophylaxis and post-exposure prophylaxis - 10 April 2020
10 April 2020
WHO R&D Blueprint COVID-19: Informal consultation on the potential inclusion of Favipiravir in a clinical trial
25 March 2020
Informal consultation on the role of IL-6/IL-1
13 March 2020
Informal consultation on the potential role of chloroquine in the clinical management of COVID 19 infection
27 January 2020
Outline of trial designs for experimental therapeutics
24 January 2020
Informal consultation on prioritization of candidate therapeutic agents for use in novel coronavirus 2019 infection
20 January 2020
Outline of designs for experimental vaccines and therapeutics - 20 January 2020
Ethics
28 May 2020
Ethical considerations to guide the use of digital proximity tracking technologies for COVID-19 contact tracing
28 May 2020
Guidance for research ethics committees for rapid review of research during public health emergencies
3 May 2020
Key criteria for the ethical acceptability of COVID-19 human challenge studies
29 March 2020
Ethical standards for research during public health emergencies: Distilling existing guidance to support COVID-19 R&D
Q&As
Social Science
29 April 2020
COVID-19 Social Science working group
29 April 2020
Perceptions of Healthcare Workers regarding local infection prevention and control procedures for COVID-19: Research protocol
23 April 2020
Working with Community Advisory Boards for COVID-19 related clinical studies
23 April 2020
R&D Good Participatory Practice for COVID-19 clinical trials: a toolbox
* Disclaimer
This website and/or database of the World Health Organization (collectively “WHO Site”) may contain links to websites, databases and/or materials developed, sponsored or maintained by third parties unaffiliated with the World Health Organization (collectively, “Third Party Sites”).
The World Health Organization (WHO) provides links to Third Party Sites solely as a convenience to users of this WHO Site. WHO makes no (and hereby disclaims any) representations, warranties or guarantees of any kind (whether express or implied) as to—and shall have no liability whatsoever arising from—any links, Third Party Sites and/or any content provided therein or accessible therefrom, including, without limitation, any representations, warranties or guarantees as to the non-infringement, fitness for a particular purpose, accuracy, completeness, subject matter, timeliness or quality of any Third Party Site or any content provided therein or accessible therefrom, and/or the use of any information (including, without limitation, personal information) that you provide to any such Third Party Sites.
The inclusion of links to any Third Party Sites shall not create any liability for WHO arising from or relating to any such links, Third Party Sites and/or any content provided therein or accessible therefrom; and your use of any and all of the foregoing is entirely at your own risk and responsibility. Accordingly, you forever hold WHO harmless from any and all claims, liabilities and/or obligations of any kind arising from or in connection with the use of any such links, Third Party Sites and/or content provided therein or accessible therefrom.
WHO reserves the right, in its sole discretion, to discontinue links to any Third Party Sites at any time for any reason. Should you leave the WHO Site via a link contained herein, the content you view in any Third Party Site is not provided or controlled by WHO. The inclusion on this WHO Site of a link to any Third Party Site does not constitute, and shall not be construed as, an endorsement, approval or recommendation by WHO of such Third Party Site and/or of any content, goods or services provided thereon or accessible therefrom.